DM506

**DM506** is a novel small molecule and synthetic derivative of ibogamine, belonging to the class of "psychoplastogens"—agents designed to rapidly and sustainably enhance neuronal plasticity without hallucinogenic or cardiotoxic side effects. DM506 inhibits both α9α10 and α7 subtypes of the nicotinic acetylcholine receptor (nAChR) via novel allosteric, non-competitive mechanisms, likely involving modulation of the extracellular-transmembrane domain junction and the cytoplasmic domain, respectively. It also decreases tonic GABA currents in the prelimbic cortex, possibly by modulating extrasynaptic GABA levels or indirect GABAA receptor inhibition. Preclinical studies show DM506 reduces cue-induced heroin-seeking behavior, producing anxiolytic- and sedative-like effects without apparent hallucinogenic or adverse psychotropic effects. Primary indications studied preclinically are opioid use disorder and anxiety-like states[1][2][3][5][7][8].

Other names

3-methyl-1,2,3,4,5,6-hexahydroazepino[4,5-b]indole fumarate